Background Cabozantinib is an oral inhibitor of tyrosine kinases including MET, VEGFR,
and AXL. The randomised phase 3 METEOR trial compared the efficacy and safety of …

Survival of patients with metastatic renal cell carcinoma (mRCC) has improved since the
advent of targeted therapy. Approved agents include the multi-targeted tyrosine kinase …

Introduction: 2-Indolinone is a well-known aromatic heterocyclic organic compound. A lot of
work has been done on this bicyclic structure by academic and company researchers to …

The introduction of targeted therapy has revolutionized the treatment of patients with
metastatic renal cell carcinoma (mRCC). The current standard of care focuses on the …

Renal-cell carcinoma (RCC) affects over 330,000 new patients every year, of whom 1/3
present with metastatic RCC (mRCC) at diagnosis. Most mRCC patients treated with a first …

Background Two risk models, the Memorial Sloan Kettering Cancer Center (MSKCC) model
and the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model …

Introduction: Agents that target the vascular endothelial growth factor (VEGF) or mammalian
target of rapamycin (mTOR) pathway as well as the PD-1 checkpoint inhibitor nivolumab are …

Introduction: Nivolumab is a recombinant, humanized monoclonal antibody that binds PD-1.
The binding of PD-1 with PD-L1, expressed on antigen-presenting cells and tumor cells …

Abstract Dectin-1, a classical pattern-recognition receptor, was now identified as an
important regulator in immune homeostasis and cancer immunity through its extensive …

Background Relative dose intensity (RDI) is a simple index for evaluation of the amount of
drug administered per unit time. We retrospectively investigated the prognostic impact of RDI …